Printer Friendly

Eisai's Tambocor(R) (Antiarrthymic Treatment) Received Approval for Paroxysmal Atrial Fibrillation/Flutter.

Tokyo, Japan, June 26, 2007 - (JCN Newswire) - Eisai Co., Ltd. announced today that an additional indication for Tambocor(R) Tablets 50 mg /100 mg (generic name: flecainide acetate) for the treatment of paroxysmal atrial fibrillation/flutter received approval in Japan.

Paroxysmal atrial fibrillation/flutter is a condition associated with tachyarrhythmia. In paroxysmal atrial fibrillation, sudden episodes of abnormal impulses occur in the atria resulting in irregular heart beats, while in paroxysmal atrial flutter, the heartbeat is in a regular rhythm, but beats rapidly. This condition causes severe palpitation and the patients with paroxysmal atrial fibrillation/flutter are also at risk of cardioembolic stroke.

In Japan, it has been reported that the number of patients with paroxysmal atrial fibrillation/flutter is estimated to be greater than one million, and also the incidence increases in parallel with age. Since the patient population is estimated to increase annually, the medical need treatment will grow in the future.

Tambocor(R) suppresses or prevents paroxysmal atrial fibrillation/flutter by blocking sodium channels. The effects of Tambocor(R) can be sustained stably with a twice-daily administration.

Eisai received approval in Japan for Tambocor(R) for the indication of ventricular tachyarrhythmia in June, 1991. This approval, together with Eisai's other related products including Warfarin(R) (anticoagulant agent) and Vasolan(R) (calcium antagonistic antiarrthymic treatment which controls increased heart rate in paroxysmal atrial fibrillation/flutter), will enable Eisai to make further contributions to patients by offering treatment options for managing paroxysmal atrial fibrillation/flutter.

About Eisai Co., Ltd.

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp.

Source: Eisai Co., Ltd.

Contact:
Corporate Communications Department
Eisai Co., Ltd.
81-3-3817-5120


Japan Corporate News Network. All rights reserved.
COPYRIGHT 2007 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Date:Jun 26, 2007
Words:336
Previous Article:Honda Publishes Honda Environmental Annual Report 2007.
Next Article:Telemark's Customer Satisfaction Report: NTT Com the Winner of Three 'Diamond Awards'.
Topics:


Related Articles
Foundation faces raising money, reconnecting with NCEW.
The ecology of genocide: the Darfur crisis has environmental roots.
A chance for sanity: the EU opens the door--finally--to debating RoHS and WEEE.
Very-low-calorie diets: downsizing the hospitalised obese patient.
He That Cometh: The Messiah Concept in the Old Testament and Later Judaism.
Construction activity is booming on the bay.
Reclamere receives NAID hard drive destruction certification.
Pennsylvania DEP gives go-ahead.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |